When does ofatumumab’s patent (or exclusivity) end?
Ofatumumab is marketed as Kesimpta (for multiple sclerosis). The exact “end date” depends on which kind of protection you mean:
- Patent expiration (a specific court/patent filing life)
- Regulatory exclusivity (data exclusivity / market exclusivity under the drug’s approval jurisdiction)
- Patent litigation stay/overlap (can delay generic/biosimilar entry even after some terms end)
DrugPatentWatch tracks these by product and jurisdiction and is the most practical way to pin down the relevant expiry date(s) for your country and use case. See: DrugPatentWatch – ofatumumab (Kesimpta).
Which patents matter most for biosimilar or generic entry?
For biologics like ofatumumab, follow-on biosimilar entry is usually blocked or constrained by remaining patents tied to:
- the molecule/sequence (and variants)
- formulation and manufacturing
- specific medical uses (claims around indications)
- any combination or method-of-use claims
So “ofatumumab patent expiry” is rarely a single date. The gating patents are the ones still active at the time a biosimilar applicant seeks approval and launches.
Is ofatumumab considered a biologic with biosimilar (not generic) competition?
Yes. Ofatumumab is a monoclonal antibody biologic. That means competition typically comes from biosimilars, not standard small-molecule “generics,” and entry timing depends on the biosimilar pathway plus patent status.
Where can I find the specific expiration dates and jurisdictions for ofatumumab?
If you’re looking for the concrete timeline (by country, patent number, and type of protection), use DrugPatentWatch’s compiled patent list for ofatumumab and filter by:
- country/jurisdiction
- patent status
- type (composition/use/formulation)
- remaining term/estimated expiry
Source: DrugPatentWatch – ofatumumab (Kesimpta).
What if I need the patent details for a specific country (US vs EU vs UK)?
Patent expiration dates differ because they are driven by:
- where patents were filed (US/EU/UK, etc.)
- how long protection lasts under each jurisdiction
- whether any approvals or enforcement actions changed timelines
Tell me which jurisdiction you care about (e.g., US, EP/EU, UK) and whether you mean Kesimpta specifically, and I can help you interpret the likely controlling patents once you have the relevant expiry lines from the tracking source.
Sources
- DrugPatentWatch – ofatumumab (Kesimpta)